Abstract: The present invention relates to solid preparations containing ambroxol which are obtainable by melt extrusion of the mixture consisting of a) 30 to 80% by weight of ambroxol hydrochloride, b) 2 to 68% by weight of at least one hydrogenated vegetable oil, c) 2 to 68% by weight of at least one mixture containing fatty acid ester and/or hydroxy fatty acid ester and d) 0 to 66% by weight of one or more pharmaceutical adjuvants, based in each case on the total amount of the preparation and its use for secretolytic treatment in acute and chronic bronchopulmonary diseases.

Abstract: The present invention provides pharmaceutical release systems comprising an therapeutically effective amount of flibanserin.

Abstract: An extended release pellet comprising an active ingredient selected from pramipexole and the pharmaceutically acceptable salts thereof, and at least one release-modifying excipient.

Abstract: The present invention relates to solid preparations containing ambroxol which are obtainable by melt extrusion of the mixture consisting of a) 30 to 80% by weight of ambroxol hydrochloride, b) 2 to 68% by weight of at least one hydrogenated vegetable oil, c) 2 to 68% by weight of at least one mixture containing fatty acid ester and/or hydroxy fatty acid ester and d) 0 to 66% by weight of one or more pharmaceutical adjuvants, based in each case on the total amount of the preparation and its use for secretolytic treatment in acute and chronic bronchopulmonary diseases.

Abstract: This invention relates to novel sodium salt forms of the following Compound (1), and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection:

Abstract: This invention relates to novel sodium salt forms of the following Compound (1), and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection:

Abstract: A dosing device for dispensing small-particulate pharmaceutical preparations has at least one chamber for receiving a larger amount of the preparation and a dosing unit. A rotary valve has at least one dosing chamber for receiving a defined dose of the preparation. The dosing chamber is moveable between a filling position and a dispensing position. The rotary valve rotates about a substantially horizontal axis, and has an adjustment device for setting the volume in the dosing chamber and a twisting device. The twisting device constitutes the actuator for the adjustment device. The device is made of a plastic material carefully selected to assure that no softening agents or other volatile components will be released, which prevents drug contamination.

Abstract: This invention relates to novel sodium salt forms of the following Compound (1), and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection:

Abstract: The present invention provides pharmaceutical release systems comprising an therapeutically effective amount of flibanserin.

Abstract: An extended release pellet comprising an active ingredient selected from pramipexole and the pharmaceutically acceptable salts thereof, and at least one release-modifying excipient.

Abstract: The invention relates to a dosing device for dosing small-particulate pharmaceutical preparations with at least one chamber for receiving a larger amount of the preparation and a dosing unit, comprising a rotary valve carrying at least one dosing chamber for receiving a defined partial amount (defined dose) of the preparation, whereby the dosing chamber is moveable between a filling position, in which it is to be filled with a preparation from the chamber, and a dispensing position, in which the preparation is to be dispensed from the dosing chamber. The rotary valve is rotable about a substantially horizontal axis, and assigned an adjustment device for setting the volume in the dosing chamber and a twisting device, whereby the twisting device constitutes the actuator for the adjustment device. The plastic material chosen such, that no softening agents or other volatile components will be released, in order to prevent drug contamination.

Abstract: A device for granulating and/or mixing, in particular for a pharmaceutical active agent formulation, comprising a cylindrical granulation chamber (10) that can be closed with a lid (31). A rotating agitator (6) is arranged at the bottom of said granulation chamber (10), and a rotatable chopper (20) is arranged around the perimeter thereof. An insert (34) reducing the holding volume is attached to the lid (31).

Abstract: An extended release pellet comprising an active ingredient selected from pramipexole and the pharmaceutically acceptable salts thereof, and at least one release-modifying excipient.

Abstract: The present invention relates to a process for preparing a ginger fraction, the fraction prepared by this process and the use thereof on its own or combined with drugs for inhibiting human cytochrome P450 (CYP) enzymes (particularly cytochrome P450 3A4, CYP3A4) for positively influencing the oral bioavailability and pharmacokinetics of active substances.

Abstract: The invention relates to the use of selected CGRP antagonists, the physiologically acceptable salts thereof or the hydrates of the hydrates of the salts thereof for combating menopausal hot flushes.

Abstract: The present invention relates to a process for the treatment or prevention of indications which are selected from among the group comprising headaches, migraine and cluster headaches, this process comprising the joint administration of a therapeutically effective amount of a selected CGRP antagonist (A), a physiologically acceptable salt thereof or a hydrate of the salt and a therapeutically effective amount of a second or third active anti-migraine medicament (B), particularly sumatriptan, zolmitriptan or dihydroergotamine or a physiologically acceptable salt thereof, and to the corresponding pharmaceutical compositions and the preparation thereof.

Abstract: The invention relates to a method of treatment or prevention of hot flushes in men who underwent castration, e.g. due to androgen ablation treatment in prostate cancer therapy, comprising administration of an effective amount of a selected CGRP antagonist to the patient, and to the use of said active compounds for the manufacture of a pharmaceutical composition intended to be used in this method.

Abstract: The invention relates to a dosing device for dosing small-particled pharmaceutical preparations, particularly preparations in the form of pellets, granules or extruded materials. The dosing device (10) shown has a chamber (16) for accommodating a larger amount of the preparation and a dosing element (22) on which is formed a dosing chamber (52), the volume of which corresponds to a defined partial quantity of the preparation, and which is movable between a filling position in which the dosing chamber (52) is to be filled with preparation from the chamber (16), and a release position in which the preparation from the dosing chamber (52) is to be dispensed from the dosing device (10). The volume of the dosing chamber (52) is adjustable for determining the defined partial quantity of preparation to be dispensed from the dosing device (10). The invention further relates to a method of dosing such preparations.

Abstract: The invention relates to a method of treatment or prevention of hot flushes in men who underwent castration, e.g. due to androgen ablation treatment in prostate cancer therapy, comprising administration of an effective amount of a selected CGRP antagonist to the patient, and to the use of said active compounds for the manufacture of a pharmaceutical composition intended to be used in this method.

Abstract: The invention relates to the use of selected CGRP antagonists, the physiologically acceptable salts thereof or the hydrates of the hydrates of the salts thereof for combating menopausal hot flushes.